Showing 3641-3650 of 19355 results for "".
Beyond the Joint: Cross-Specialty Solutions for Advancing TGCT Patient Care
https://reachmd.com/programs/cme/beyond-the-joint-cross-specialty-solutions-for-advancing-tgct-patient-care/36596/Explore TGCT recognition, clinical evidence, treatment strategies, and management of adverse events with CSF1R inhibitors in an interdisciplinary context.Chairperson’s Perspective: Precision in Practice: Advancing EGFR-Altered Metastatic NSCLC Through Guideline-Concordant, Case-Based Learning
https://reachmd.com/programs/cme/chairpersons-perspective-precision-in-practice-advancing-egfr-altered-metastatic-nsclc-through-guideline-concordant-case-based-learning/33808/Improve patient outcomes in EGFR-mutated metastatic NSCLC through timely molecular testing, evidence-based treatment, and team-based management of AEs.Schizophrenia and Heart Health: Navigating the Hidden Risk of Sudden Cardiac Death
https://reachmd.com/programs/neurofrontiers/schizophrenia-and-heart-health-navigating-the-hidden-risk-of-sudden-cardiac-death/27075/Learn about strategies to improve both mental and heart health in schizophrenia patients to reduce the risk of sudden cardiac death.Exploring the Emergency Use Authorization for a Monoclonal Antibody Cocktail for COVID-19
https://reachmd.com/programs/the-drug-report/exploring-the-emergency-use-authorization-for-a-monoclonal-antibody-cocktail-for-covid-19/12025/Here’s what led the FDA to issue an EUA for the coadministration of casirivimab and imdevimab to block COVID-19’s attachment and entry into cells.Chloroquine as a Treatment Agent for COVID-19: Hype or Hope?
https://reachmd.com/programs/covid-19-frontlines/chloroquine-treatment-agent-covid-19-hype-or-hope/11323/Will the antimalarial drug chloroquine and its derivative, hydroxychloroquine, become effective COVID-19 treatment and prophylaxis agents?The Future of HNSCC: Aligning Teams, Transforming Care
https://reachmd.com/programs/cme/The-Future-of-HNSCC-Aligning-Teams-Transforming-Care/54394/Practice-changing data in resectable HNSCC? Experts unpack KEYNOTE-689, NIVOPOSTOP, and how to implement perioperative immunotherapy.Understanding the Skin–Mind Connection in Neurocosmetics
https://reachmd.com/ma-issues-index/march-april-2026-issue/understanding-the-skinmind-connection-in-neurocosmetics/56636/Neurocosmetics tap the skin–brain axis to influence both cutaneous function and emotional well-beingExpert Consensus Addresses Complication Management in Ablative Facial Resurfacing
https://reachmd.com/programs/modern-aesthetics/expert-consensus-addresses-complication-management-in-ablative-facial-resurfacing/56629/High-impact resurfacing demands high-level complication managementProgress and Practical Limits with AI in Psoriatic Arthritis
https://reachmd.com/programs/Audioabstracts/progress-practical-limits-ai-psoriatic-arthritis/51047/Artificial intelligence is reshaping the landscape of psoriatic arthritis, offering new tools to improve diagnosis, risk assessment, and treatment response prediction. Hear Ryan Quigley discuss a narrative review that looked at emerging AI innovations in rheumatology and how they may enhance care foRethinking the Therapeutic Targeting of B7-H3 in ES-SCLC
https://reachmd.com/programs/cme/rethinking-the-therapeutic-targeting-of-b7-h3-in-es-sclc/37876/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.